Evired Selected as an Investment Program For The Future by the French National Research Agency

This work has been selected by the French National Research Agency as an investment program for the Future (reference ANR-18-RHUS-0008) and will benefits from state aid

EviRed (Intelligent Evaluation of Diabetic Retinopathy) has been selected in June 2019 between 67 RHU (University Hospital Research programs) files submitted as one of the 15 projects which will benefits from a five-year state financial support. The official start date of the program was February 2020.

This program is under the overside of Pr Ramin Tadayoni, Professor of Ophthalmology at Université de Paris University and Head of Ophthalmology Department at Lariboisière University Hospital (Paris, France). The program is managed by AP-HP, and other academic partners are UBO-LATIM and Université de Paris.  Several private partners are also involved and invest in this program: ADCIS, Evolucare and Carl Zeiss-Meditec.

Share This Post